1Burch HB, Wartofsky L. Gravest ophthalmopathy: current concepts regarding pathogenesis and management [ J ] , Endocr Rev, 1993,14 (6) : 747-793,.
2Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy[ J]. N Engl J Med, 1993,329(20) : 1468-1475.
3Gerding MN,Terwee CB, Dekker FW, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument [ J ]. Thyroid, 1997,7 (6) : 885-889.
4Geoffrey J, Gladstone MD. Opbthalmologic aspects of thyroid-related orbitopathy[ J]. Endocrinol Metab Clin North Am, 1998,27 ( 1 ) :91-100.
6Mouritis MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach[J] ,Br J Ophthalmol,1989,73(8) :639-644.
7Mouritis IMP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves'ophthalmopathy[J].Clin Endocrinol(Oxf),1997,47(1):9-14.
8Pete P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy[ J ]. Clin Endocrinol (Oxf), 1995,42( 1 ) : 45-50.
9Bartley GB, Fatourechi V, Kadrmas EF, et al. The treatment of Graves'ophthalmopathy in an incidence cohort [ J ]. Am J Ophthalmol, 1996,121(2) :200-206.
7Tsujino K, Hirota S, Hagiwara M,et al. Clinical outcomes of orbital irradiation with or without systemic high-dose or corticosteroids for Graves'ophthalmopathy. Int J Radio Oncol Biol Phys,2000,48:857-864.
8Schaefer U, Hesselmann S, Micke O,et al. A long-tem follow-up study after retro-orbital irradiation for patients with progressive Graves' ophthalmopathy. Int J Radio Oncol Biol Phys,2002,52 : 192-197.
9Marquez S D, Lure B L, Mcdougall I R, et al. Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radio Oncol Biol Phys,2001,51:766-774.
